Cleo Diagnostics (ASX:COV) ROE % Adjusted to Book Value: -5.73% (As of Dec. 2025)


ASX:COV Cleo Diagnostics Ltd ASX:COV
17 GF Score
Price A$0.50
! 1 Warning Sign
View Full Analysis

What is Cleo Diagnostics ROE % Adjusted to Book Value?

Cleo Diagnostics ASX:COV +2.04% 17 ROE % Adjusted to Book Value is -5.73% as of Dec. 2025. GuruFocus rates ASX:COV with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Cleo Diagnostics's ROE % for the quarter that ended in Dec. 2025 was -54.11%. Cleo Diagnostics's PB Ratio for the quarter that ended in Dec. 2025 was 9.45. Cleo Diagnostics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -5.73%.

Cleo Diagnostics ROE % Adjusted to Book Value Related Terms

Cleo Diagnostics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Cleo Diagnostics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cleo Diagnostics ROE % Adjusted to Book Value Chart

Cleo Diagnostics Annual Data
Trend Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
0.00 -18.97 -5.61

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial -51.09 -5.30 -7.06 -7.12 -5.73

ASX:COV vs ABT, SYK, MDT: ROE % Adjusted to Book Value Comparison

For the Medical Devices subindustry, Cleo Diagnostics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's ROE % Adjusted to Book Value falls into.


ASX:COV
17GF Score
Cleo Diagnostics Ltd ASX:COV
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cleo Diagnostics ROE % Adjusted to Book Value Calculation

Cleo Diagnostics's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-48.64% / 8.67
=-5.61%

Cleo Diagnostics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-54.11% / 9.45
=-5.73%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -5.73% mean?
Cleo Diagnostics (ASX:COV) has a ROE % Adjusted to Book Value of -5.73% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Cleo Diagnostics and its competitors.
Is Cleo Diagnostics' ROE % Adjusted to Book Value too high?
Cleo Diagnostics' current ROE % Adjusted to Book Value is -5.73%. Overall, Cleo Diagnostics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' ROE % Adjusted to Book Value compare to ABT and SYK?
Cleo Diagnostics' ROE % Adjusted to Book Value of -5.73% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Cleo Diagnostics and its competitors. Cleo Diagnostics's current ROE % Adjusted to Book Value is -5.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current ROE % Adjusted to Book Value of -5.73%. The current ROE % Adjusted to Book Value is -5.73%. Cleo Diagnostics' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current ROE % Adjusted to Book Value is -5.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cleo Diagnostics Business Description

Address 480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
17GF Score

Get the complete analysis for ASX:COV

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.50
Price